http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20050019903-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2003-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20050019903-A |
| titleOfInvention | Azaindole Kinase Inhibitors |
| abstract | The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. Compounds of formula (I) inhibit tyrosine kinase activity of proliferative factor receptors such as VEGFR-2 and FGFR-1 and are therefore useful as anticancer agents. Compounds of formula (I) are also useful for the treatment of other diseases associated with signaling pathways that operate through proliferation factor receptors.n n n <Formula I> |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10573496-B2 |
| priorityDate | 2002-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 552.